At the q3w RP2D, three of ten ovarian cancer patients revealed confirmed partial responses, with durations of 2.7, 3.6, and 4.1 months and an additional three patients showed a CA125 response without a RECIST response. This evidence concerns the gene MUC16 and ovarian cancer.